Clinical Trials Logo

Pioglitazone clinical trials

View clinical trials related to Pioglitazone.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03566225 Completed - Pioglitazone Clinical Trials

Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome

Start date: January 30, 2018
Phase: Early Phase 1
Study type: Interventional

Participants with PCOS will be divided into two groups then each group will randomly recieve one of the following treatment 1. metformin will be adminstered in adose of 500 mg 3 times daily for 3 months to group B. 2. pioglitazone will be administered in adose of 30 mg dialy for 3 months to group A. 3. Induction of ovulation by clomiphene citate 50 mg tablets to all participants

NCT ID: NCT01309854 Completed - Healthy Volunteers Clinical Trials

Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects

Start date: March 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the drug interaction between fostamatinib and pioglitazone by comparing the safety, tolerability and plasma concentration of pioglitazone when administered alone and with fostamatinib in healthy subjects.

NCT ID: NCT01258322 Completed - Inflammation Clinical Trials

Pioglitazone Attenuates Dysmetabolism in Peritoneal Dialysis (PD) Patients

Start date: January 2008
Phase: N/A
Study type: Interventional

1. Background:Cardiovascular disease (CVD) is the major cause of mortality in peritoneal dialysis (PD) patients, in whom it is partly attributable to a higher prevalence of dysmetabolism. Currently, few treatments are available with a proven effect on dyslipidemia, insulin resistance and inflammation in this patient group. 2. Study design: Randomized, cross-over trial. 3. Settings and Participants: Prevalent PD patients (>20 years old, s-triglycerides >1.8 mmol/L) who had never received glitazones were enrolled. 4. Interventions: Participants were randomized to receive either oral pioglitazone (PIO; 15 mg once daily) and no pioglitazone, both for 12 weeks and in random order, with a four-week wash out in between. 5. Outcomes and measurements: The primary endpoint was change of serum triglyceride (TG) level during the PIO as compared to no PIO. Secondary endpoints included changes in other lipid levels, HOMA-IR, adipocytokines and CRP. Outcome effects were assessed using a GLM.